Patent Oppositions Summary
EPO in 2023
Why is it important to track oppositions?
2000+ oppositions are filed each year at the EPO. Tracking outcome is important since it can influence your generic launch strategy. It also gives an indication as to which companies are eating away your market share.
spacer_11
At a Glance
650
oppositions filed
Photos
730
law firms involved
Reviews
spacer_11
Top 10 companies facing oppositions
Name Opposition count
Novartis AG 48
GlaxoSmithKline Biologicals SA 43
Boehringer Ingelheim International GmbH 27
Procter and Gamble Co 21
Nutricia NV 14
Eisai R&D Management Co Ltd 14
Stada Arzneimittel AG 14
Amgen Inc 14
LOreal SA 9
Novo Nordisk AS 9
spacer_11
Top 10 companies who filed oppositions
Name Opposition count
Generics UK 26
Sandoz 22
Henkel 18
Strawman 15
JG Oppositions 14
Teva Pharmaceutical Industries 14
Convatec 12
Sanofi 12
Nicoventures Trading 11
Stada Arzneimittel 11
Do you know?

Amylin Pharmaceutical's patent (EP2347762B1) used Exendin to treat diabetes and reducing body weight. However the patent was revoked in Dec-2023 after oppositions raised by not just one but multiple parties.

Top 15 patents facing oppositions
Patent Applicant Opposition count
EP3294283B1 Novartis AG 16
EP2959894B1 Novartis AG 12
EP2981255B1 Boehringer Ingelheim International GmbH 10
EP3524595B1 Eisai R&D Management Co Ltd 9
EP3324937B1 Stada Arzneimittel AG 8
EP3694483B1 Procter and Gamble Co 8
EP3448416B1 Novo Nordisk AS 8
EP3578175B1 Amgen Inc 7
EP3067043B1 Novartis AG 6
EP3768304B1 Institut National de la Sante et de la Recherche Medicale INSERM 6
EP3324936B1 Stada Arzneimittel AG 6
EP2611467B1 GlaxoSmithKline Biologicals SA 5
EP3597216B1 ER Squibb and Sons LLC 5
EP3266306B1 Schuelke and Mayr GmbH 5
EP3265122B1 Eisai R&D Management Co Ltd 5
© 2024 GreyB Research